Polo-Like Kinase 1 as a Potential Therapeutic Target for Osteosarcoma

Author(s): Li Cheng , Chongchong Wang , Juehua Jing .

Journal Name: Current Pharmaceutical Design

Volume 21 , Issue 10 , 2015


Osteosarcoma is the most common primary bone malignancy of adolescents and young adults. Existing treatment options and surgical intervention are unable to effectively manage this tumor. Therefore, novel mechanism-based targets and strategies need to be rationally established to strive for improvement in the survival of patients diagnosed with osteosarcoma. The serine/threonine kinases Polo-like kinase (Plk) 1 is a key regulator of cell division in eukaryotic cells. Plk1 gene and protein expression has been proposed as a new prognostic marker for many types of malignancies, and Plk1 is a potential target for cancer therapy. In this review, we shall discuss the studies which indicate that Plk1 could be an excellent target for the treatment of osteosarcoma.

Keywords: Plk1, osteosarcoma, cancer, therapy, target.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2015
Page: [1347 - 1350]
Pages: 4
DOI: 10.2174/1381612820999141029162811
Price: $58

Article Metrics

PDF: 33